Trump Opened A $400 Billion Mental Health Market… But Buffett Would Watch The Trap First

A new regulatory door may be opening for psychedelic-assisted mental health treatments, and investors are rushing toward small biotech names tied to depression, PTSD, and treatment-resistant conditions. This Warren Buffett-style story explains why the opportunity is real but dangerous: approval is not profit, clinical data is not commercialization, patents are not guaranteed, and small biotech upside always comes with dilution, reimbursement, and execution risk. The lesson is not to chase hype. It is to study the machine before buying the story. Disclaimer: This is an independent, educational fan channel and is not affiliated with Warren Buffett or Berkshire Hathaway. AI-generated voices are used for storytelling and educational purposes only. This content is not financial advice. #WarrenBuffett #PsychedelicStocks #BiotechInvesting #MentalHealth #InvestingWisdom #StockMarket #CompassPathways #RiskManagement #WealthBuilding #FinancialFreedom